Wellington Management Group LLP Lowers Position in IDEAYA Biosciences, Inc. $IDYA

Wellington Management Group LLP lowered its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 8.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,486 shares of the company’s stock after selling 3,304 shares during the period. Wellington Management Group LLP’s holdings in IDEAYA Biosciences were worth $598,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Oppenheimer Asset Management Inc. raised its holdings in shares of IDEAYA Biosciences by 33.2% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company’s stock valued at $189,000 after acquiring an additional 2,884 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of IDEAYA Biosciences by 9.6% in the 1st quarter. Rhumbline Advisers now owns 124,437 shares of the company’s stock valued at $2,038,000 after acquiring an additional 10,876 shares in the last quarter. Palumbo Wealth Management LLC raised its holdings in shares of IDEAYA Biosciences by 65.8% in the 1st quarter. Palumbo Wealth Management LLC now owns 22,402 shares of the company’s stock valued at $367,000 after acquiring an additional 8,893 shares in the last quarter. Swiss National Bank raised its holdings in shares of IDEAYA Biosciences by 0.8% in the 1st quarter. Swiss National Bank now owns 150,800 shares of the company’s stock valued at $2,470,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of IDEAYA Biosciences by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock valued at $83,417,000 after acquiring an additional 14,535 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

IDYA opened at $24.55 on Tuesday. The stock’s 50 day simple moving average is $23.33 and its 200 day simple moving average is $20.49. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $40.25. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -6.48 and a beta of 0.12.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analyst estimates of $3.48 million. During the same quarter last year, the firm posted ($0.68) EPS. IDEAYA Biosciences’s revenue was up NaN% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on IDYA. Wells Fargo & Company started coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They issued an “overweight” rating and a $44.00 price target on the stock. The Goldman Sachs Group upgraded IDEAYA Biosciences to a “hold” rating and set a $25.00 price objective on the stock in a research report on Thursday, July 10th. TD Cowen started coverage on IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a “buy” rating on the stock. JPMorgan Chase & Co. increased their price objective on IDEAYA Biosciences from $66.00 to $72.00 and gave the company an “overweight” rating in a research report on Monday, July 28th. Finally, Royal Bank Of Canada upgraded IDEAYA Biosciences from an “outperform” rating to a “moderate buy” rating and reduced their price objective for the company from $57.00 to $30.00 in a research report on Wednesday, July 9th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $47.10.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.